id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2011-N-0231-0015,FDA,FDA-2011-N-0231,Agency Information Collection Activities; Announcement of Office of Management and Budget Approvals,Notice,Notice of Approval,2021-05-19T04:00:00Z,2021,5,2021-05-19T04:00:00Z,,2023-09-07T21:10:22Z,2021-10535,0,0,0900006484b1b36a
FDA-2011-N-0231-0013,FDA,FDA-2011-N-0231,"Agency Information Collection Activities; Submission for Office of Management and Budget Review;
Comment Request; Adverse Experience Reporting for Licensed Biological Products; and General Records",Notice,30 Day Proposed Information Collection,2021-02-23T05:00:00Z,2021,2,2021-02-23T05:00:00Z,2021-03-26T03:59:59Z,2023-09-07T21:09:23Z,2021-03541,0,0,0900006484a47c79
FDA-2011-N-0231-0011,FDA,FDA-2011-N-0231,Agency Information Collection Activities: Proposed Collection; Comment Request; Adverse Experience Reporting for Licensed Biological Products; and General  Records,Notice,60 Day Proposed Information Collection,2020-09-01T04:00:00Z,2020,9,2020-09-01T04:00:00Z,2020-11-03T04:59:59Z,2023-09-07T21:08:45Z,2020-19239,0,0,090000648482d8bb
FDA-2011-N-0231-0010,FDA,FDA-2011-N-0231,"Agency Information Collection Activities; Announcement of Office of
Management and Budget Approvals",Notice,Notice of Approval,2018-06-08T04:00:00Z,2018,6,2018-06-08T04:00:00Z,,2023-09-07T21:07:07Z,2018-12338,0,0,090000648337b830
FDA-2011-N-0231-0009,FDA,FDA-2011-N-0231,Agency Information Collection Activities; Submission for Office of Management and Budget Review; Adverse Experience Reporting for Licensed Biological Products; and General Records,Notice,30 Day Proposed Information Collection,2018-01-08T05:00:00Z,2018,1,2018-01-08T05:00:00Z,2018-02-08T04:59:59Z,2023-09-07T21:06:53Z,2018-00095,0,0,0900006482db13e0
FDA-2011-N-0231-0008,FDA,FDA-2011-N-0231,Agency Information Collection Activities; Proposed Collection; Comment Request; Adverse Experience Reporting for Licensed Biological Products; and General Records,Notice,60 Day Proposed Information Collection,2017-07-18T04:00:00Z,2017,7,2017-07-18T04:00:00Z,2017-09-19T03:59:59Z,2023-09-07T21:06:37Z,2017-15004,0,0,090000648293b6b2
FDA-2011-N-0231-0007,FDA,FDA-2011-N-0231,"Agency Information Collection Activities; Submission for Office of
Management and Budget Review; Comment Request; Adverse
Experience Reporting for Licensed Biological Products; and General
Records",Notice,30 Day Proposed Information Collection,2014-10-29T04:00:00Z,2014,10,2014-10-29T04:00:00Z,2014-11-29T04:59:59Z,2014-11-28T03:00:48Z,2014-25637,0,0,0900006481905358
FDA-2011-N-0231-0005,FDA,FDA-2011-N-0231,"Agency Information Collection Activities; Proposed Collection;
Comment Request; Adverse Experience Reporting for Licensed
Biological Products; and General Records",Notice,60 Day Proposed Information Collection,2014-04-07T04:00:00Z,2014,4,2014-04-07T04:00:00Z,2014-06-07T03:59:59Z,2014-10-16T21:34:25Z,2014-07711,0,0,09000064816a301b
FDA-2011-N-0231-0004,FDA,FDA-2011-N-0231,"Agency Information Collection Activities; Proposals, Submissions, and Approvals",Notice,Notice of Approval,2011-11-25T05:00:00Z,2011,11,2011-11-25T05:00:00Z,,2011-11-25T14:16:51Z,2011-30326,0,0,0900006480f73634
FDA-2011-N-0231-0003,FDA,FDA-2011-N-0231,"Agency Information Collection Activities; Proposals, Submissions, and Approvals: Adverse Experience Reporting for Licensed Biological Products; and General Records",Notice,General Notice,2011-07-14T04:00:00Z,2011,7,2011-07-14T04:00:00Z,2011-08-16T03:59:59Z,2011-07-14T13:39:05Z,2011-17675,0,0,0900006480ec1c64
FDA-2011-N-0231-0001,FDA,FDA-2011-N-0231,"Agency Information Collection Activities; Proposals, Submissions, and Approvals: Adverse Experience Reporting for Licensed Biological Products and General Records",Notice,N-Notice,2011-04-21T04:00:00Z,2011,4,2011-04-21T04:00:00Z,2011-06-21T03:59:59Z,2011-04-21T13:59:28Z,2011-09651,0,0,0900006480c34c8b